Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 193 to 203 of 203 entries
Sorted by: Best Match Show Resources per page
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma.

medRxiv : the preprint server for health sciences

Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF.
PMID: 34981068
medRxiv. 2021 Dec 21; doi: 10.1101/2021.12.10.21267485.

BACKGROUND: The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain.METHODS: This multicenter, double-blind randomized controlled trial compared the efficacy and safety of SARS-CoV-2 high titer...

Cite
Sullivan DJ, Gebo KA, Shoham S, et al. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv. 2021;doi: 10.1101/2021.12.10.21267485.
Sullivan, D. J., Gebo, K. A., Shoham, S., Bloch, E. M., Lau, B., Shenoy, A. G., Mosnaim, G. S., Gniadek, T. J., Fukuta, Y., Patel, B., Heath, S. L., Levine, A. C., Meisenberg, B. R., Spivak, E. S., Anjan, S., Huaman, M. A., Blair, J. E., Currier, J. S., Paxton, J. H., Gerber, J. M., Petrini, J. R., Broderick, P. B., Rausch, W., Cordisco, M. E., Hammel, J., Greenblatt, B., Cluzet, V. C., Cruser, D., Oei, K., Abinante, M., Hammitt, L. L., Sutcliffe, C. G., Forthal, D. N., Zand, M. S., Cachay, E. R., Raval, J. S., Kassaye, S. G., Foster, E. C., Roth, M., Marshall, C. E., Yarava, A., Lane, K., McBee, N. A., Gawad, A. L., Karlen, N., Singh, A., Ford, D. E., Jabs, D. A., Appel, L. J., Shade, D. M., Ehrhardt, S., Baksh, S. N., Laeyendecker, O., Pekosz, A., Klein, S. L., Casadevall, A., Tobian, A. A. R., & Hanley, D. F. (2021). Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.12.10.21267485
Sullivan, David J, et al. "Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.12.10.21267485
Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv. 2021 Dec 21; doi: 10.1101/2021.12.10.21267485. PMID: 34981068; PMCID: PMC8722611.
Copy Download .nbib Format: NLM
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma.

medRxiv : the preprint server for health sciences

Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF.
PMID: 34981068
medRxiv. 2021 Dec 21; doi: 10.1101/2021.12.10.21267485.

BACKGROUND: The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain.METHODS: This multicenter, double-blind randomized controlled trial compared the efficacy and safety of SARS-CoV-2 high titer...

Cite
Sullivan DJ, Gebo KA, Shoham S, et al. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv. 2021;doi: 10.1101/2021.12.10.21267485.
Sullivan, D. J., Gebo, K. A., Shoham, S., Bloch, E. M., Lau, B., Shenoy, A. G., Mosnaim, G. S., Gniadek, T. J., Fukuta, Y., Patel, B., Heath, S. L., Levine, A. C., Meisenberg, B. R., Spivak, E. S., Anjan, S., Huaman, M. A., Blair, J. E., Currier, J. S., Paxton, J. H., Gerber, J. M., Petrini, J. R., Broderick, P. B., Rausch, W., Cordisco, M. E., Hammel, J., Greenblatt, B., Cluzet, V. C., Cruser, D., Oei, K., Abinante, M., Hammitt, L. L., Sutcliffe, C. G., Forthal, D. N., Zand, M. S., Cachay, E. R., Raval, J. S., Kassaye, S. G., Foster, E. C., Roth, M., Marshall, C. E., Yarava, A., Lane, K., McBee, N. A., Gawad, A. L., Karlen, N., Singh, A., Ford, D. E., Jabs, D. A., Appel, L. J., Shade, D. M., Ehrhardt, S., Baksh, S. N., Laeyendecker, O., Pekosz, A., Klein, S. L., Casadevall, A., Tobian, A. A. R., & Hanley, D. F. (2021). Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.12.10.21267485
Sullivan, David J, et al. "Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.12.10.21267485
Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv. 2021 Dec 21; doi: 10.1101/2021.12.10.21267485. PMID: 34981068; PMCID: PMC8722611.
Copy Download .nbib Format: NLM
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.

Cell reports

Joyce MG, Chen WH, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Martinez EJ, Chang WC, Peterson CE, Morrison EB, Smith C, Chen RE, Ahmed A, Wieczorek L, Anderson A, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-Rivera L, Karch CP, Gohain N, Villar Z, McCurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Soman S, Kuklis C, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, McTamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K.
PMID: 34919799
Cell Rep. 2021 Dec 08;110143. doi: 10.1016/j.celrep.2021.110143. Epub 2021 Dec 08.

The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize four categories of engineered...

Cite
Joyce MG, Chen WH, Sankhala RS, et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 2021;110143doi: 10.1016/j.celrep.2021.110143.
Joyce, M. G., Chen, W. H., Sankhala, R. S., Hajduczki, A., Thomas, P. V., Choe, M., Martinez, E. J., Chang, W. C., Peterson, C. E., Morrison, E. B., Smith, C., Chen, R. E., Ahmed, A., Wieczorek, L., Anderson, A., Case, J. B., Li, Y., Oertel, T., Rosado, L., Ganesh, A., Whalen, C., Carmen, J. M., Mendez-Rivera, L., Karch, C. P., Gohain, N., Villar, Z., McCurdy, D., Beck, Z., Kim, J., Shrivastava, S., Jobe, O., Dussupt, V., Molnar, S., Tran, U., Kannadka, C. B., Soman, S., Kuklis, C., Zemil, M., Khanh, H., Wu, W., Cole, M. A., Duso, D. K., Kummer, L. W., Lang, T. J., Muncil, S. E., Currier, J. R., Krebs, S. J., Polonis, V. R., Rajan, S., McTamney, P. M., Esser, M. T., Reiley, W. W., Rolland, M., de Val, N., Diamond, M. S., Gromowski, G. D., Matyas, G. R., Rao, M., Michael, N. L., & Modjarrad, K. (2021). SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell reports, 110143. https://doi.org/10.1016/j.celrep.2021.110143
Joyce, M Gordon, et al. "SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity." Cell reports vol. (2021): 110143. doi: https://doi.org/10.1016/j.celrep.2021.110143
Joyce MG, Chen WH, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Martinez EJ, Chang WC, Peterson CE, Morrison EB, Smith C, Chen RE, Ahmed A, Wieczorek L, Anderson A, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-Rivera L, Karch CP, Gohain N, Villar Z, McCurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Soman S, Kuklis C, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, McTamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 2021 Dec 08;110143. doi: 10.1016/j.celrep.2021.110143. Epub 2021 Dec 08. PMID: 34919799.
Copy Download .nbib Format: NLM
C1 and C2 Fractures Above a Previous Fusion Treated with Internal Fixation without Fusion: A Case Report.

JBJS case connector

Kolz JM, Hobson SL, Currier BL, Nassr AN.
PMID: 33979831
JBJS Case Connect. 2021 Apr 14;11(2). doi: 10.2106/JBJS.CC.20.00672.

CASE: A 71-year-old woman sustained C1 lateral mass and type 2 odontoid fractures 3 years after C2-T2 anterior-posterior fusion. She was treated with C1-C4 instrumentation without fusion for 9 months followed by instrumentation removal to restore atlantoaxial motion. After...

Cite
Kolz JM, Hobson SL, Currier BL, et al. C1 and C2 Fractures Above a Previous Fusion Treated with Internal Fixation without Fusion: A Case Report. JBJS Case Connect. 2021;11(2)doi: 10.2106/JBJS.CC.20.00672.
Kolz, J. M., Hobson, S. L., Currier, B. L., & Nassr, A. N. (2021). C1 and C2 Fractures Above a Previous Fusion Treated with Internal Fixation without Fusion: A Case Report. JBJS case connector, 11(2), . https://doi.org/10.2106/JBJS.CC.20.00672
Kolz, Joshua M, et al. "C1 and C2 Fractures Above a Previous Fusion Treated with Internal Fixation without Fusion: A Case Report." JBJS case connector vol. 11,2 (2021). doi: https://doi.org/10.2106/JBJS.CC.20.00672
Kolz JM, Hobson SL, Currier BL, Nassr AN. C1 and C2 Fractures Above a Previous Fusion Treated with Internal Fixation without Fusion: A Case Report. JBJS Case Connect. 2021 Apr 14;11(2). doi: 10.2106/JBJS.CC.20.00672. PMID: 33979831.
Copy Download .nbib Format: NLM
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.

medRxiv : the preprint server for health sciences

Boucau J, Chew KW, Choudhary M, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK.
PMID: 35018382
medRxiv. 2021 Dec 30; doi: 10.1101/2021.12.25.21268211.

Monoclonal antibodies (mAbs) are the treatment of choice for high-risk ambulatory persons with mild to moderate COVID-19. We studied viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial. Viral load by...

Cite
Boucau J, Chew KW, Choudhary M, et al. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. medRxiv. 2021;doi: 10.1101/2021.12.25.21268211.
Boucau, J., Chew, K. W., Choudhary, M., Deo, R., Regan, J., Flynn, J. P., Crain, C. R., Hughes, M. D., Ritz, J., Moser, C., Dragavon, J. A., Javan, A. C., Nirula, A., Klekotka, P., Greninger, A. L., Coombs, R. W., Fischer, W. A., Daar, E. S., Wohl, D. A., Eron, J. J., Currier, J. S., Smith, D. M., Li, J. Z., Barczak, A. K. (2021). Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.12.25.21268211
Boucau, Julie, et al. "Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.12.25.21268211
Boucau J, Chew KW, Choudhary M, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. medRxiv. 2021 Dec 30; doi: 10.1101/2021.12.25.21268211. PMID: 35018382; PMCID: PMC8750705.
Copy Download .nbib Format: NLM
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.

Cell reports

Joyce MG, Chen WH, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Martinez EJ, Chang WC, Peterson CE, Morrison EB, Smith C, Chen RE, Ahmed A, Wieczorek L, Anderson A, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-Rivera L, Karch CP, Gohain N, Villar Z, McCurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Soman S, Kuklis C, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, McTamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K.
PMID: 34919799
Cell Rep. 2021 Dec 08;110143. doi: 10.1016/j.celrep.2021.110143. Epub 2021 Dec 08.

The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize four categories of engineered...

Cite
Joyce MG, Chen WH, Sankhala RS, et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 2021;110143doi: 10.1016/j.celrep.2021.110143.
Joyce, M. G., Chen, W. H., Sankhala, R. S., Hajduczki, A., Thomas, P. V., Choe, M., Martinez, E. J., Chang, W. C., Peterson, C. E., Morrison, E. B., Smith, C., Chen, R. E., Ahmed, A., Wieczorek, L., Anderson, A., Case, J. B., Li, Y., Oertel, T., Rosado, L., Ganesh, A., Whalen, C., Carmen, J. M., Mendez-Rivera, L., Karch, C. P., Gohain, N., Villar, Z., McCurdy, D., Beck, Z., Kim, J., Shrivastava, S., Jobe, O., Dussupt, V., Molnar, S., Tran, U., Kannadka, C. B., Soman, S., Kuklis, C., Zemil, M., Khanh, H., Wu, W., Cole, M. A., Duso, D. K., Kummer, L. W., Lang, T. J., Muncil, S. E., Currier, J. R., Krebs, S. J., Polonis, V. R., Rajan, S., McTamney, P. M., Esser, M. T., Reiley, W. W., Rolland, M., de Val, N., Diamond, M. S., Gromowski, G. D., Matyas, G. R., Rao, M., Michael, N. L., & Modjarrad, K. (2021). SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell reports, 110143. https://doi.org/10.1016/j.celrep.2021.110143
Joyce, M Gordon, et al. "SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity." Cell reports vol. (2021): 110143. doi: https://doi.org/10.1016/j.celrep.2021.110143
Joyce MG, Chen WH, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Martinez EJ, Chang WC, Peterson CE, Morrison EB, Smith C, Chen RE, Ahmed A, Wieczorek L, Anderson A, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-Rivera L, Karch CP, Gohain N, Villar Z, McCurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Soman S, Kuklis C, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, McTamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 2021 Dec 08;110143. doi: 10.1016/j.celrep.2021.110143. Epub 2021 Dec 08. PMID: 34919799; PMCID: PMC8651551.
Copy Download .nbib Format: NLM
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.

bioRxiv : the preprint server for biology

Wuertz KM, Barkei EK, Chen WH, Martinez EJ, Lakhal-Naouar I, Jagodzinski LL, Paquin-Proulx D, Gromowski GD, Swafford I, Ganesh A, Dong M, Zeng X, Thomas PV, Sankhala RS, Hajduczki A, Peterson CE, Kuklis C, Soman S, Wieczorek L, Zemil M, Anderson A, Darden J, Hernandez H, Grove H, Dussupt V, Hack H, de la Barrera R, Zarling S, Wood JF, Froude JW, Gagne M, Henry AR, Mokhtari EB, Mudvari P, Krebs SJ, Pekosz AS, Currier JR, Kar S, Porto M, Winn A, Radzyminski K, Lewis MG, Vasan S, Suthar M, Polonis VR, Matyas GR, Boritz EA, Douek DC, Seder RA, Daye SP, Rao M, Peel SA, Gordon Joyce M, Bolton DL, Michael NL, Modjarrad K.
PMID: 34159328
bioRxiv. 2021 Jun 16; doi: 10.1101/2021.06.16.448525.

The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the B.1.1.7 and B.1.351 VOCs...

Cite
Wuertz KM, Barkei EK, Chen WH, et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters. bioRxiv. 2021;doi: 10.1101/2021.06.16.448525.
Wuertz, K. M., Barkei, E. K., Chen, W. H., Martinez, E. J., Lakhal-Naouar, I., Jagodzinski, L. L., Paquin-Proulx, D., Gromowski, G. D., Swafford, I., Ganesh, A., Dong, M., Zeng, X., Thomas, P. V., Sankhala, R. S., Hajduczki, A., Peterson, C. E., Kuklis, C., Soman, S., Wieczorek, L., Zemil, M., Anderson, A., Darden, J., Hernandez, H., Grove, H., Dussupt, V., Hack, H., de la Barrera, R., Zarling, S., Wood, J. F., Froude, J. W., Gagne, M., Henry, A. R., Mokhtari, E. B., Mudvari, P., Krebs, S. J., Pekosz, A. S., Currier, J. R., Kar, S., Porto, M., Winn, A., Radzyminski, K., Lewis, M. G., Vasan, S., Suthar, M., Polonis, V. R., Matyas, G. R., Boritz, E. A., Douek, D. C., Seder, R. A., Daye, S. P., Rao, M., Peel, S. A., Gordon Joyce, M., Bolton, D. L., Michael, N. L., & Modjarrad, K. (2021). A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.06.16.448525
Wuertz, Kathryn McGuckin, et al. "A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.06.16.448525
Wuertz KM, Barkei EK, Chen WH, Martinez EJ, Lakhal-Naouar I, Jagodzinski LL, Paquin-Proulx D, Gromowski GD, Swafford I, Ganesh A, Dong M, Zeng X, Thomas PV, Sankhala RS, Hajduczki A, Peterson CE, Kuklis C, Soman S, Wieczorek L, Zemil M, Anderson A, Darden J, Hernandez H, Grove H, Dussupt V, Hack H, de la Barrera R, Zarling S, Wood JF, Froude JW, Gagne M, Henry AR, Mokhtari EB, Mudvari P, Krebs SJ, Pekosz AS, Currier JR, Kar S, Porto M, Winn A, Radzyminski K, Lewis MG, Vasan S, Suthar M, Polonis VR, Matyas GR, Boritz EA, Douek DC, Seder RA, Daye SP, Rao M, Peel SA, Gordon Joyce M, Bolton DL, Michael NL, Modjarrad K. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters. bioRxiv. 2021 Jun 16; doi: 10.1101/2021.06.16.448525. PMID: 34159328; PMCID: PMC8219092.
Copy Download .nbib Format: NLM
Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection.

Frontiers in immunology

Wegman AD, Fang H, Rothman AL, Thomas SJ, Endy TP, McCracken MK, Currier JR, Friberg H, Gromowski GD, Waickman AT.
PMID: 34899736
Front Immunol. 2021 Nov 24;12:777672. doi: 10.3389/fimmu.2021.777672. eCollection 2021.

Dengue virus (DENV) is a prevalent human pathogen, infecting approximately 400 million individuals per year and causing symptomatic disease in approximately 100 million. A distinct feature of dengue is the increased risk for severe disease in some individuals with...

Cite
Wegman AD, Fang H, Rothman AL, et al. Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection. Front Immunol. 2021;12:777672doi: 10.3389/fimmu.2021.777672.
Wegman, A. D., Fang, H., Rothman, A. L., Thomas, S. J., Endy, T. P., McCracken, M. K., Currier, J. R., Friberg, H., Gromowski, G. D., & Waickman, A. T. (2021). Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection. Frontiers in immunology, 12777672. https://doi.org/10.3389/fimmu.2021.777672
Wegman, Adam D, et al. "Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection." Frontiers in immunology vol. 12 (2021): 777672. doi: https://doi.org/10.3389/fimmu.2021.777672
Wegman AD, Fang H, Rothman AL, Thomas SJ, Endy TP, McCracken MK, Currier JR, Friberg H, Gromowski GD, Waickman AT. Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection. Front Immunol. 2021 Nov 24;12:777672. doi: 10.3389/fimmu.2021.777672. eCollection 2021. PMID: 34899736; PMCID: PMC8654368.
Copy Download .nbib Format: NLM
Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation.

Journal of acquired immune deficiency syndromes (1999)

Kousari A, Moser C, Olefsky M, Brown TT, Currier JS, McComsey GA, Scherzinger A, Stein JH, Lake JE, Erlandson KM.
PMID: 34326283
J Acquir Immune Defic Syndr. 2021 Dec 01;88(4):399-405. doi: 10.1097/QAI.0000000000002776.

BACKGROUND: We have previously shown that the initiation of antiretroviral therapy (ART) is associated with a decrease in skeletal muscle density (greater fat accumulation), suggesting that gains in lean body mass seen in many ART studies may reflect gains...

Cite
Kousari A, Moser C, Olefsky M, et al. Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation. J Acquir Immune Defic Syndr. 2021;88(4):399-405doi: 10.1097/QAI.0000000000002776.
Kousari, A., Moser, C., Olefsky, M., Brown, T. T., Currier, J. S., McComsey, G. A., Scherzinger, A., Stein, J. H., Lake, J. E., & Erlandson, K. M. (2021). Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation. Journal of acquired immune deficiency syndromes (1999), 88(4), 399-405. https://doi.org/10.1097/QAI.0000000000002776
Kousari, Arianna, et al. "Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation." Journal of acquired immune deficiency syndromes (1999) vol. 88,4 (2021): 399-405. doi: https://doi.org/10.1097/QAI.0000000000002776
Kousari A, Moser C, Olefsky M, Brown TT, Currier JS, McComsey GA, Scherzinger A, Stein JH, Lake JE, Erlandson KM. Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation. J Acquir Immune Defic Syndr. 2021 Dec 01;88(4):399-405. doi: 10.1097/QAI.0000000000002776. PMID: 34326283; PMCID: PMC8556226.
Copy Download .nbib Format: NLM
Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta.

Canadian journal of pain = Revue canadienne de la douleur

Boitor M, Gélinas C, Rauch F, Jacob E, LeMay S, Carrier JI, Bilodeau C, Tsimicalis A.
PMID: 35005403
Can J Pain. 2019 Jul 18;3(1):148-156. doi: 10.1080/24740527.2019.1626705. eCollection 2019.

No abstract available.

Cite
Boitor M, Gélinas C, Rauch F, et al. Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta. Can J Pain. 2019;3(1):148-156doi: 10.1080/24740527.2019.1626705.
Boitor, M., Gélinas, C., Rauch, F., Jacob, E., LeMay, S., Carrier, J. I., Bilodeau, C., & Tsimicalis, A. (2019). Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta. Canadian journal of pain = Revue canadienne de la douleur, 3(1), 148-156. https://doi.org/10.1080/24740527.2019.1626705
Boitor, Madalina, et al. "Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta." Canadian journal of pain = Revue canadienne de la douleur vol. 3,1 (2019): 148-156. doi: https://doi.org/10.1080/24740527.2019.1626705
Boitor M, Gélinas C, Rauch F, Jacob E, LeMay S, Carrier JI, Bilodeau C, Tsimicalis A. Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta. Can J Pain. 2019 Jul 18;3(1):148-156. doi: 10.1080/24740527.2019.1626705. eCollection 2019. PMID: 35005403; PMCID: PMC8730568.
Copy Download .nbib Format: NLM
Caffeine Timing Improves Lower-Body Muscular Performance: A Randomized Trial.

Frontiers in nutrition

Harty PS, Zabriskie HA, Stecker RA, Currier BS, Tinsley GM, Surowiec K, Jagim AR, Richmond SR, Kerksick CM.
PMID: 33330586
Front Nutr. 2020 Nov 23;7:585900. doi: 10.3389/fnut.2020.585900. eCollection 2020.

Little is known about the optimal time to consume caffeine prior to exercise to maximize the ergogenic benefits of the substance.

Cite
Harty PS, Zabriskie HA, Stecker RA, et al. Caffeine Timing Improves Lower-Body Muscular Performance: A Randomized Trial. Front Nutr. 2020;7:585900doi: 10.3389/fnut.2020.585900.
Harty, P. S., Zabriskie, H. A., Stecker, R. A., Currier, B. S., Tinsley, G. M., Surowiec, K., Jagim, A. R., Richmond, S. R., & Kerksick, C. M. (2020). Caffeine Timing Improves Lower-Body Muscular Performance: A Randomized Trial. Frontiers in nutrition, 7585900. https://doi.org/10.3389/fnut.2020.585900
Harty, Patrick S, et al. "Caffeine Timing Improves Lower-Body Muscular Performance: A Randomized Trial." Frontiers in nutrition vol. 7 (2020): 585900. doi: https://doi.org/10.3389/fnut.2020.585900
Harty PS, Zabriskie HA, Stecker RA, Currier BS, Tinsley GM, Surowiec K, Jagim AR, Richmond SR, Kerksick CM. Caffeine Timing Improves Lower-Body Muscular Performance: A Randomized Trial. Front Nutr. 2020 Nov 23;7:585900. doi: 10.3389/fnut.2020.585900. eCollection 2020. PMID: 33330586; PMCID: PMC7719671.
Copy Download .nbib Format: NLM
Showing 193 to 203 of 203 entries